Case report
Open access
Aug 2026
FGFR2 fusion as the key to targeted therapy - a case report with a diagnostic turning point.
Targeted therapy with FGFR tyrosine kinase inhibitors, particularly in the presence of the FGFR3-TACC3 gene fusion, is capable of inducing long-term remission even in advanced disease previously treated with multiple modalities, as evidenced by the observations.
M. Pesek, M. Drosslerová, Tomáš Vaněček et al.
· Klinicka onkologie · 0 citations